**AGILE: team bios**

**Andrew Owen, PhD FRSB FBPhSFLSW**

Professor of Pharmacology, University of Liverpool

Andrew Owen is Professor of Pharmacology and Director of the Centre of Excellence in Long-acting Therapeutics (CELT) at the University of Liverpool. He is Chair of the British Society for Nanomedicine, a fellow of the Royal Society of Biology, a fellow of the British Pharmacological Society, and a fellow of the Learned Society of Wales. His clinical and basic research focuses on understanding mechanisms that underpin inter-patient variability in pharmacokinetics and pharmacodynamics. A major emphasis has been to employ knowledge of these mechanisms to accelerate the translation of technologies to clinical applications for oral and long-acting drug delivery. He has published over 240 peer-reviewed papers and book chapters and is co-inventor of patents relating to drug delivery. Professor Owen is principle investigator for LONGEVITY which is a $40m project that aims to translate novel long-acting medicines for malaria chemoprophylaxis, tuberculosis prevention and Hepatitis C Virus therapy. Other funding has been secured from USAID, NIH, EPSRC, MRC as well as charitable and industry funders. He also co-leads the UK contribution to the H2020-funded European Nanomedicine Characterisation Laboratory ([www.EUNCL.eu](http://www.euncl.eu/)) and a modelling core for the NIH-funded Long-acting/Extended release Antiretroviral resource Program ([www.LEAPresources.org](http://www.leapresources.org/)).

**David Lalloo, MB, BS, MD, FRCP, FFTM, RCPS**

Director & Professor of Tropical Medicine, Liverpool School of Tropical Medicine (LSTM)

Having undergone initial training in Newcastle upon Tyne, David Lalloo trained in General (Internal) Medicine, Infectious Diseases and Tropical Medicine, spending three years in Papua New Guinea. He undertook clinical and laboratory research in Oxford before moving as Senior Lecturer to the Liverpool School of Tropical Medicine in 1999. Since then he has focused on clinical trials in the tropics, particularly in HIV related infections, malaria and envenoming. He currently has collaborations and studies in a number of countries including Malawi, Uganda, Sri Lanka, Vietnam, Kenya, Nigeria, eSwatini and South Africa. He has worked with the MLW Programme in Malawi for almost twenty years. He holds an appointment as an Honorary Consultant at the Royal Liverpool University Hospital and remains clinically active.

Prior to taking up the Directorship of LSTM in January 2019, David was Dean of Clinical Sciences and International Public Health and was Director of the Wellcome Trust Liverpool Glasgow Centre for Global Health Research and the Liverpool Wellcome Trust Clinical PhD Programme. He has a strong interest in identifying and supporting young UK clinicians interested in tropical research and strengthening scientific capacity in resource poor settings. He continues to supervise PhD and MD students in a wide variety of infection related areas.

**Andrea Corkhill**

Andrea Corkhill is Head of Trial Management at Southampton Clinical Trials Unit (SCTU). She has been working in clinical trials for more than 20 years, and has expertise in many aspects of clinical trial conduct. Andrea leads the trial management team within SCTU, with a particular focus on oncology and early phase COVID-19 clinical trials.

**Gareth Griffiths, BSc, MSc, PhD**

Director, Southampton Clinical Trials Unit (SCTU), University of Southampton

Professor of Clinical Trials, Centre of Cancer Immunology, University of Southampton

Gareth Griffiths is the Director of the UKCRC registered Southampton Clinical Trials Unit (SCTU) and Professor of Clinical Trials based at the Centre of Cancer Immunology at the University of Southampton. Southampton SCTU is a Cancer Research UK core funded SCTU and working very closely with the National Cancer Research Institute Clinical Studies Groups Gareth has developed and conducted numerous phase 1-3 trials in cancer.

**Helen Reynolds**

Programme Manager in Pharmacology and Therapeutics at the University of Liverpool

Helen Reynolds is also an Honorary Clinical Research Nurse at Liverpool University Hospitals NHS Foundation Trust. She is a programme manager for the clinical trials in Prof. Saye Khoo’s antiviral research group that include the international DolPHIN consortium and AGILE.

**Lauren Walker, BSc, MBChB, PhD, MRCP**

NIHR Clinical Lecturer in Clinical Pharmacology & Therapeutics

Lauren Walker is also Honorary Consultant Physician in Clinical Pharmacology and Associate Director of the NIHR Clinical Research Facility at Liverpool University Hospitals NHS Foundation Trust.

**Sir Michael Jacobs, PhD**

Clinical Director of Infection, Royal Free Hospital

Michael Jacobs is Clinical Director of Infection at the Royal Free Hospital in London. He trained at Oxford and London universities before completing a PhD in Virology. He is interested in all aspects of clinical infectious diseases with a special interest in serious viral infections and medical countermeasures. He is director of the UK High Level Isolation Unit and is a member of the UK Advisory Committee on Dangerous Pathogens. He worked at the centre of the UK response to the West Africa Ebola outbreak, and serves on several national and international Ebola advisory committees. He was NHS England Programme Director for High Consequence Infectious Diseases. He was knighted in 2016 for services to the prevention and treatment of infectious diseases.

**Richard FitzGerald, PhD**

Director of the NIHR Clinical Research Facility and a Consultant Physician in Clinical Pharmacology and Therapeutics / General Medicine at the Royal Liverpool University Hospital

Richard FitzGerald is a qualified first-in-man principal investigator as part of the CRF’s MHRA Phase I accreditation. Richard has been involved in early phase clinical trials for over 10 years, including periods working in industry. He has been a director of the CRF since 2011 and has been principal investigator on many early phase and first-in-man studies (including patient cohorts and healthy volunteers) over the last five years. Richard has particular interests in the design and analysis of early phase trials in patient groups and the development of novel pharmacodynamic techniques to generate proof of principle in both healthy volunteers and patients.

Richard is also an honorary senior lecturer in the Wolfson Centre for Personalised Medicine, where his major research interests include stratified therapies in cardiovascular disease, optimisation of anti-platelet therapy, adverse drug reactions and systematic reviews and meta-analyses.

Richard remains an active clinician with a range of practice across inpatient general medicine, toxicology, hypertension and adverse drug reactions.

**Saye Khoo, MB, BS, MRCP, DTM&H, FRCP, MD**

Professor of Pharmacology and Therapeutics at the University of Liverpool, and Honorary Consultant Physician in Infectious Disease at Liverpool University Hospitals NHS Foundation Trust

Saye Khoo leads a research programme in antiviral therapy and is Chief Investigator for the international DolPHIN consortium and for AGILE. Research interests include optimisation of antivirals to treat or prevent HIV, including in special populations such as pregnant women and newborn infants. This work is underpinned by highly sensitive drug measurement in his GCP-accredited laboratory, and mathematical modelling to predict drug exposure within body compartments and between people. The study of drug-drug interactions has led to development of the Liverpool Drug Interactions Prescribing Resource for HIV, hepatitis, cancer and in 2020 for experimental COVID-19 therapies. These are widely accessed and used by treatment guidelines throughout the world (including WHO), returning 18M searches in the past 3 years. Khoo has served in expert advisory groups and guidelines committees for the British HIV Association, WHO, British Infection Society, UK Home Office, British Transplant Society, European Society for Organ Transplantation and the International AIDS Society.

**Susannah Condie**

Head of Clinical Data Management at Southampton Clinical Trials Unit (SCTU), University of Southampton

Susannah Condie is a clinical operations professional with 30 years' experience, across both academia and pharmaceutical research development, specialising in clinical data management and digital technology. Susannah has led the digital transformation at SCTU, including the implementation of Software as a Service [SaaS] and Medidata Rave EDC, integrated randomisation RTSM and eConsent.

**Tom Fletcher, MD, PhD**

Consultant in the Tropical Infectious Disease Unit in Liverpool and Senior Clinical Lecturer at the Liverpool School of Tropical Medicine (LSTM)

Tom Fletcher is a physician in the Defence Medical Services and specialises in the clinical management on High-Consequence Infectious Diseases. He has active research programmes in Turkey, Sudan and Sierra Leone and is part of the HQ WHO clinical team for COVID-19.

**Thomas Jaki, MS, PhD**

Professor of Statistics at Lancaster University and Programme Leader at the MRC Biostatistics Unit at the University of Cambridge

Thomas Jaki’s work focuses on efficient trials using adaptive and Bayesian methods. He is also the Director of the Medical and Pharmaceutical Statistics Research Unit which offers advice on the design and analysis of clinical studies and develops relevant novel statistical methods. He is an NIHR senior research fellow and Co-I of the Trials Methodology Research Partnership and co-leads its adaptive designs working group.

He has worked with WHO on the COVID-19 core protocol used in the SOLIDARITY trial, been involved in one of the first randomized COVID-19 trials in Wuhan (Cao et al, 2020) and one of the first studies investigating remdesivir for COVID patients (Wang et al, 2020). He is Co-I and member of the trial steering committee for the national platform trial RECOVERY ([www.recoverytrial.net](http://www.recoverytrial.net)).